May 8th 2024
Phase 2 data also highlight an improvement in disease control rate with setanaxib/pembrolizumab in squamous cell carcinoma of the head and neck.
Vitamin A Derivative Does Not Prevent Second Primary Tumors in Head and Neck Cancer Patients
September 6th 2017Chemoprevention with low-dose 13-Cis retinoic acid, a synthetic vitamin A derivative, did not lower the incidence of second primary tumors in patients with squamous cell cancer of the head and neck.
Nivolumab Approved for Squamous Cell Carcinoma of the Head and Neck
November 14th 2016The US Food and Drug Administration (FDA) in record time has approved nivolumab (Opdivo) for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after a platinum-based therapy.